Efficacy of Treatment of Non-hereditary Angioedema
| العنوان: | Efficacy of Treatment of Non-hereditary Angioedema |
|---|---|
| المؤلفون: | Henderikus G. Otten, Mignon T. van den Elzen, André C. Knulst, M. F. C. L. Go, H. van Os-Medendorp, Mark A. Blankestijn |
| المصدر: | Clinical Reviews in Allergy & Immunology, 54(3), 412. Humana Press Clinical Reviews in Allergy & Immunology |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | medicine.medical_specialty, Angiotensin-Converting Enzyme Inhibitors, Omalizumab, Pharmacology, Bradykinin, Article, 03 medical and health sciences, Ecallantide, chemistry.chemical_compound, 0302 clinical medicine, Refractory, Icatibant, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Angioedema, business.industry, Wheals, General Medicine, Idiopathic, medicine.disease, Dermatology, Treatment, Treatment Outcome, Tranexamic Acid, 030228 respiratory system, chemistry, Angiotensin-converting enzyme inhibitor, Hereditary angioedema, Fresh frozen plasma, Progestins, medicine.symptom, business, Tranexamic acid, medicine.drug |
| الوصف: | Non-hereditary angioedema (AE) with normal C1 esterase inhibitor (C1INH) can be presumably bradykinin- or mast cell-mediated, or of unknown cause. In this systematic review, we searched PubMed, EMBASE, and Scopus to provide an overview of the efficacy of different treatment options for the abovementioned subtypes of refractory non-hereditary AE with or without wheals and with normal C1INH. After study selection and risk of bias assessment, 61 articles were included for data extraction and analysis. Therapies were described for angiotensin-converting enzyme inhibitor-induced AE (ACEi-AE), for idiopathic AE, and for AE with wheals. Described treatments consisted of ecallantide, icatibant, C1INH, fresh frozen plasma (FFP), tranexamic acid (TA), and omalizumab. Additionally, individual studies for anti-vitamin K, progestin, and methotrexate were found. Safety information was available in 26 articles. Most therapies were used off-label and in few patients. There is a need for additional studies with a high level of evidence. In conclusion, in acute attacks of ACEi-AE and idiopathic AE, treatment with icatibant, C1INH, TA, and FFP often leads to symptom relief within 2 h, with limited side effects. For prophylactic treatment of idiopathic AE and AE with wheals, omalizumab, TA, and C1INH were effective and safe in the majority of patients. |
| وصف الملف: | image/pdf |
| اللغة: | English |
| تدمد: | 1080-0549 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76684d06cb7b812e508c342324064445Test https://dspace.library.uu.nl/handle/1874/376369Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....76684d06cb7b812e508c342324064445 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10800549 |
|---|